Esbriet

December 15, 2015December 15, 2015

New IPF Study to Test OFEV/Esbriet as Combination Therapy

Boehringer Ingelheim announced that it has initiated a 12-week clinical trial investigating the safety, tolerability, and pharmacokinetics of pirfenidone (marketed as Esbriet by Genentech) as an add-on to treatment with OFEV (nintedanib). The ... Read more

August 13, 2015November 5, 2015

American Thoracic Society Recommends Esbriet (Pirfenidone) in Updated IPF Treatment Guidelines

Idiopathic Pulmonary Fibrosis, News

Esbriet (pirfenidone) by Genentech was recently included in the American Thoracic Society’s (ATS) updated idiopathic pulmonary fibrosis (IPF) treatment guidelines, which presents the drug’s proven benefits in delaying disease progression, as determined ... Read more

August 3, 2015November 5, 2015

Roche’s Pirfenidone (Esbriet) Found to Offer Therapeutic Benefit For IPF in a Clinical Practice Setting

Idiopathic Pulmonary Fibrosis, News

A new study recently published in the journal Advances in Therapy provided evidence of the therapeutic benefit of pirfenidone (known by the brand name Esbriet) for IPF patients in a ... Read more

July 2, 2015November 6, 2015

Study Presented at EULAR Shows Roche’s Esbriet Meets Safety Targets in Systemic Sclerosis-related Interstitial Lung Disease

News, Scleroderma

Results from a recent open-label trial presented during the European League Against Rheumatism Annual European Congress of Rheumatology showed that ESBRIET met its safety endpoint in the treatment of interstitial lung ... Read more